The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

New Delhi [India], December 23: Surmount Logistics, Chennai being a startup company incorporated only in the year 2022, strongly believe that their employees are considered to be the primary reason ...

Jefferies analysts weighed in, noting that CagriSema’s 20.4% weight loss at 68 weeks closely mirrored the 20.9% seen in Lilly’s Tirzepatide (15mg) at 72 weeks in the SURMOUNT-1 trial. However, while ...

Jastreboff A, Aronne L, Ahmad N, et al. (2022) Tirzepatide once weekly for the treatment of obesity. New Eng J Med 387: 205–16 (SURMOUNT-1) Garvey W, Frias J, Jastreboff A, et al. (2023) Tirzepatide ...

Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management.

Clinical trial results from competitors were largely underwhelming, including this week’s REDEFINE-1 phase 3 results of Novo Nordisk’s (NVO) CagriSema, and Eli Lilly delivered superior weight ...